Loading…
Reported covered position: Leg Director, Rep Bob Franks (1197-2000) Leg Correspondent, Rep Charles Taylor (1997) Leg Correspondent, Rep Bill Martini (1995-1996)
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
H.R. 3561, the PATIENT Act of 2023, provisions related to lab price reporting
Consolidated Appropriations Act, 2024
Client: MYRIAD GENETICS, INC. · Firm: MYRIAD GENETICS, INC.
H.R. 4366, the Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2024 - report language related to precision medicine for treatment of depression in veterans
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
MYRIAD GENETICS, INC. via MYRIAD GENETICS, INC.
2023 · fourth_quarter · Q4
FDA rulemaking to regulate laboratory developed tests
S708 - legislation to require CMS to issue a dear Medicaid director letter concerning precision medicine for depression Regulations governing Medicare Advantage plans and the use of prior authorization
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Source: Senate LDA
Consolidated Appropriations Act, 2024
Client: MYRIAD GENETICS, INC. · Firm: MYRIAD GENETICS, INC.
H.R. 4366, the Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2024 - report language related to precision medicine for treatment of depression in veterans
Support for Patients and Communities Reauthorization Act
Client: MYRIAD GENETICS, INC. · Firm: MYRIAD GENETICS, INC.
S708 - legislation to require CMS to issue a dear Medicaid director letter concerning precision medicine for depression H.R. 4531, the Support for Patients and Communities Reauthorization Act
A bill to improve outcomes for Medicaid beneficiaries with major depressive disorder or other mental health conditions.
Client: MYRIAD GENETICS, INC. · Firm: MYRIAD GENETICS, INC.
S708 - legislation to require CMS to issue a dear Medicaid director letter concerning precision medicine for depression Regulations governing Medicare Advantage plans and the use of prior authorization
A bill to improve outcomes for Medicaid beneficiaries with major depressive disorder or other mental health conditions.
Client: MYRIAD GENETICS, INC. · Firm: MYRIAD GENETICS, INC.
S708 - legislation to require CMS to issue a dear Medicaid director letter concerning precision medicine for depression
A bill to improve outcomes for Medicaid beneficiaries with major depressive disorder or other mental health conditions.
Client: MYRIAD GENETICS, INC. · Firm: MYRIAD GENETICS, INC.
S708 - legislation to require CMS to issue a dear Medicaid director letter concerning precision medicine for depression H.R. 4531, the Support for Patients and Communities Reauthorization Act
A bill to improve outcomes for Medicaid beneficiaries with major depressive disorder or other mental health conditions.
Client: MYRIAD GENETICS, INC. · Firm: MYRIAD GENETICS, INC.
S708 - legislation to require CMS to issue a dear medicaid director letter concerning precision medicine for depression Legislation not introduced related to in person visits for high-cost lab tests ordered in Medicare
Regulation of laboratory developed tests - "Verifying Accurate, Leading-edge IVCT Development (VALID) Act" (HR 4128 / S 2209)
Regulation of laboratory developed tests - "Verifying Accurate, Leading-edge IVCT Development (VALID) Act" (HR 4128 / S 2209)
Regulation of laboratory developed tests - "Verifying Accurate, Leading-edge IVCT Development (VALID) Act" (HR 4128 / S 2209)
Regulation of laboratory developed tests - "Verifying Accurate, Leading-edge IVCT Development (VALID) Act" (HR 4128 / S 2209)
Telehealth Extension Act of 2021
Client: MYRIAD GENETICS, INC. · Firm: MYRIAD GENETICS, INC.
Mental health legislation; no draft, no bill introduced - access to genetic testing for mental health treatment decisions Telehealth provisions following PHE; HR6202/S3593 - provisions requiring in person visits prior to ordering lab tests
Telehealth Extension Act of 2021
Client: MYRIAD GENETICS, INC. · Firm: MYRIAD GENETICS, INC.
Mental health legislation; no draft, no bill introduced - access to genetic testing for mental health treatment decisions Telehealth provisions following PHE; HR6202/S3593 - provisions requiring in person visits prior to ordering lab tests
Telehealth Extension Act of 2021
Client: MYRIAD GENETICS, INC. · Firm: MYRIAD GENETICS, INC.
Telehealth provisions following PHE; HR6202/S3593 - provisions requiring in person visits prior to ordering lab tests Legislation on best practices for pharmacogenomic testing; S4633
Telehealth Extension Act of 2021
Client: MYRIAD GENETICS, INC. · Firm: MYRIAD GENETICS, INC.
Mental health legislation; no draft, no bill introduced - access to genetic testing for mental health treatment decisions Telehealth provisions following PHE; HR6202/S3593 - provisions requiring in person visits prior to ordering lab tests
Regulation of laboratory developed tests - "Verifying Accurate, Leading-edge IVCT Development (VALID) Act" (HR 4128 / S 2209)
Regulation of laboratory developed tests - "Verifying Accurate, Leading-edge IVCT Development (VALID) Act" (HR 4128 / S 2209)
Regulation of laboratory developed tests - "Verifying Accurate, Leading-edge IVCT Development (VALID) Act" (HR 4128 / S 2209)
Regulation of laboratory developed tests - "Verifying Accurate, Leading-edge IVCT Development (VALID) Act" (HR 4128 / S 2209)
Telehealth Extension and Evaluation Act
Client: MYRIAD GENETICS, INC. · Firm: MYRIAD GENETICS, INC.
Mental health legislation; no draft, no bill introduced - access to genetic testing for mental health treatment decisions Telehealth provisions following PHE; HR6202/S3593 - provisions requiring in person visits prior to ordering lab tests
Telehealth Extension and Evaluation Act
Client: MYRIAD GENETICS, INC. · Firm: MYRIAD GENETICS, INC.
Telehealth provisions following PHE; HR6202/S3593 - provisions requiring in person visits prior to ordering lab tests Legislation on best practices for pharmacogenomic testing; S4633
Telehealth Extension and Evaluation Act
Client: MYRIAD GENETICS, INC. · Firm: MYRIAD GENETICS, INC.
Mental health legislation; no draft, no bill introduced - access to genetic testing for mental health treatment decisions Telehealth provisions following PHE; HR6202/S3593 - provisions requiring in person visits prior to ordering lab tests
Telehealth Extension and Evaluation Act
Client: MYRIAD GENETICS, INC. · Firm: MYRIAD GENETICS, INC.
Mental health legislation; no draft, no bill introduced - access to genetic testing for mental health treatment decisions Telehealth provisions following PHE; HR6202/S3593 - provisions requiring in person visits prior to ordering lab tests
A bill to improve outcomes for Medicaid beneficiaries with major depressive disorder or other mental health conditions.
Client: MYRIAD GENETICS, INC. · Firm: MYRIAD GENETICS, INC.
Telehealth provisions following PHE; HR6202/S3593 - provisions requiring in person visits prior to ordering lab tests Legislation on best practices for pharmacogenomic testing; S4633
Regulation of laboratory developed tests - "Verifying Accurate, Leading-edge IVCT Development (VALID) Act" (HR 4128 / S 2209)
Regulation of laboratory developed tests - "Verifying Accurate, Leading-edge IVCT Development (VALID) Act" (HR 4128 / S 2209)
Regulation of laboratory developed tests - "Verifying Accurate, Leading-edge IVCT Development (VALID) Act" (HR 4128 / S 2209)
Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2022
Client: MYRIAD GENETICS, INC. · Firm: MYRIAD GENETICS, INC.
FY22 House and Senate MilCon/VA appropriations (HR 4355); access to depression treatments for veterans
Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2022
Client: MYRIAD GENETICS, INC. · Firm: MYRIAD GENETICS, INC.
FY22 House and Senate MilCon/VA appropriations (HR 4355); access to depression treatments for veterans
Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2022
Client: MYRIAD GENETICS, INC. · Firm: MYRIAD GENETICS, INC.
FY22 House and Senate MilCon/VA appropriations (HR 4355); access to depression treatments for veterans
Telehealth Extension Act of 2021
Client: MYRIAD GENETICS, INC. · Firm: MYRIAD GENETICS, INC.
Mental health legislation; no draft, no bill introduced - access to genetic testing for mental health treatment decisions Telehealth provisions following PHE; HR 6202/no Senate number - provisions requiring in person visits prior to ordering lab tests
Regulation of laboratory developed tests - "Verifying Accurate, Leading-edge IVCT Development (VALID) Act" (HR 4128 / S 2209)
Regulation of laboratory developed tests - "Verifying Accurate, Leading-edge IVCT Development (VALID) Act" (HR 4128 / S 2209)
Regulation of laboratory developed tests - "Verifying Accurate, Leading-edge IVCT Development (VALID) Act" (HR 4128 / S 2209)
Regulation of laboratory developed tests e.g. pharmacogenomics LDTs - discussion draft in House - "Verifying Accurate, Leading-edge IVCT Development (VALID) Act of 2020" - HR 6102/S 3404 Provisions relating to laboratories in PL 115-271 Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act; Section 8122
Regulation of laboratory developed tests "Verifying Accurate, Leading-edge IVCT Development (VALID) Act of 2020" - HR 6102/S 3404
Regulation of laboratory developed tests "Verifying Accurate, Leading-edge IVCT Development (VALID) Act of 2020" - HR 6102/S 3404 Provisions relating to laboratories in PL 115-271 Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act; Section 8122
Regulation of laboratory developed tests e.g. pharmacogenomics LDTs - discussion draft in House - "Verifying Accurate, Leading-edge IVCT Development (VALID) Act of 2020" - HR 6102/S 3404 Provisions relating to laboratories in PL 115-271 Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act; Section 8122
S. 1895, the Lower Health Care Costs Act - Title I, Ending Surprise Medical Bills
Regulation of laboratory developed tests "Verifying Accurate, Leading-edge IVCT Development (VALID) Act of 2020" - HR 6102/S 3404
Regulation of laboratory developed tests e.g. pharmacogenomics LDTs - discussion draft in House - "Verifying Accurate, Leading-edge IVCT Development (VALID) Act of 2020" - HR 6102/S 3404 Provisions relating to laboratories in PL 115-271 Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act; Section 8122
Regulation of laboratory developed tests e.g. pharmacogenomics LDTs - discussion draft in House - "Verifying Accurate, Leading-edge IVCT Development (VALID) Act of 2020" - HR 6102/S 3404 Provisions relating to laboratories in PL 115-271 Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act; Section 8122
Regulation of laboratory developed tests "Verifying Accurate, Leading-edge IVCT Development (VALID) Act of 2020" - HR 6102/S 3404 Provisions relating to laboratories in PL 115-271 Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act; Section 8122
S. 1895, the Lower Health Care Costs Act - Title I, Ending Surprise Medical Bills
S. 1895, the Lower Health Care Costs Act - Title I, Ending Surprise Medical Bills
S. 1895, the Lower Health Care Costs Act - Title I, Ending Surprise Medical Bills
Local Coverage Determination Clarification Act of 2018
Client: MYRIAD GENETICS, INC. · Firm: MYRIAD GENETICS, INC.
Section 216(a) of the Protecting Access to Medicare Act of 2014 (PAMA)(PL 113-93); payment, coding and coverage for laboratory tests HR 3635, Local Coverage Determination Clarification Act of 2017; LCD process for laboratory tests
2023 · third_quarter · Q3
H.R. 4366, the Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2024 - report language related to precision medicine for treatment of depression in veterans
S708 - legislation to require CMS to issue a dear Medicaid director letter concerning precision medicine for depression
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MYRIAD GENETICS, INC. via MYRIAD GENETICS, INC.
2023 · second_quarter · Q2
H.R. 4366, the Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2024 - report language related to precision medicine for treatment of depression in veterans
H.R. 3561, the PATIENT Act of 2023, provisions related to lab price reporting
S708 - legislation to require CMS to issue a dear Medicaid director letter concerning precision medicine for depression H.R. 4531, the Support for Patients and Communities Reauthorization Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MYRIAD GENETICS, INC. via MYRIAD GENETICS, INC.
2023 · first_quarter · Q1
FY2024 MilCon VA Appropriations bills not yet introduced; provisions related to precision medicine for treatment of depression in veterans
S708 - legislation to require CMS to issue a dear medicaid director letter concerning precision medicine for depression Legislation not introduced related to in person visits for high-cost lab tests ordered in Medicare
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MYRIAD GENETICS, INC. via MYRIAD GENETICS, INC.
2022 · fourth_quarter · Q4
FY23 House and Senate MilCon/VA appropriations; access to depression treatments for veterans
Regulation of laboratory developed tests - "Verifying Accurate, Leading-edge IVCT Development (VALID) Act" (HR 4128 / S 2209)
Telehealth provisions following PHE; HR6202/S3593 - provisions requiring in person visits prior to ordering lab tests Legislation on best practices for pharmacogenomic testing; S4633
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MYRIAD GENETICS, INC. via MYRIAD GENETICS, INC.
2022 · third_quarter · Q3
Mental health legislation; no draft, no bill introduced - access to genetic testing for mental health treatment decisions Telehealth provisions following PHE; HR6202/S3593 - provisions requiring in person visits prior to ordering lab tests
Regulation of laboratory developed tests - "Verifying Accurate, Leading-edge IVCT Development (VALID) Act" (HR 4128 / S 2209)
FY23 House and Senate MilCon/VA appropriations; access to depression treatments for veterans
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MYRIAD GENETICS, INC. via MYRIAD GENETICS, INC.
2022 · second_quarter · Q2
FY23 House and Senate MilCon/VA appropriations; access to depression treatments for veterans
Regulation of laboratory developed tests - "Verifying Accurate, Leading-edge IVCT Development (VALID) Act" (HR 4128 / S 2209)
Mental health legislation; no draft, no bill introduced - access to genetic testing for mental health treatment decisions Telehealth provisions following PHE; HR6202/S3593 - provisions requiring in person visits prior to ordering lab tests
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MYRIAD GENETICS, INC. via MYRIAD GENETICS, INC.
2022 · first_quarter · Q1
Regulation of laboratory developed tests - "Verifying Accurate, Leading-edge IVCT Development (VALID) Act" (HR 4128 / S 2209)
Mental health legislation; no draft, no bill introduced - access to genetic testing for mental health treatment decisions Telehealth provisions following PHE; HR6202/S3593 - provisions requiring in person visits prior to ordering lab tests
FY23 House and Senate MilCon/VA appropriations; access to depression treatments for veterans
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MYRIAD GENETICS, INC. via MYRIAD GENETICS, INC.
2021 · fourth_quarter · Q4
Regulation of laboratory developed tests - "Verifying Accurate, Leading-edge IVCT Development (VALID) Act" (HR 4128 / S 2209)
Mental health legislation; no draft, no bill introduced - access to genetic testing for mental health treatment decisions Telehealth provisions following PHE; HR 6202/no Senate number - provisions requiring in person visits prior to ordering lab tests
FY22 House and Senate MilCon/VA appropriations (HR 4355); access to depression treatments for veterans
MYRIAD GENETICS, INC. via MYRIAD GENETICS, INC.
2021 · third_quarter · Q3
FY22 House and Senate MilCon/VA appropriations (HR 4355); access to depression treatments for veterans
Section 216(a) of PL 113-93 (Protecting Access to Medicare Act of 2014; aka PAMA) - payment of laboratory tests in Medicare
Mental health legislation; no draft, no bill introduced - access to genetic testing for mental health treatment decisions Telehealth provisions following PHE; no bill introduced - provisions requiring in person visits prior to ordering lab tests
MYRIAD GENETICS, INC. via MYRIAD GENETICS, INC.
2021 · second_quarter · Q2
FY22 House and Senate MilCon/VA appropriations (HR 4355); access to depression treatments for veterans
Regulation of laboratory developed tests - "Verifying Accurate, Leading-edge IVCT Development (VALID) Act" (HR 4128 / S 2209)
Section 216(a) of PL 113-93 (Protecting Access to Medicare Act of 2014; aka PAMA) - payment of laboratory tests in Medicare
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MYRIAD GENETICS, INC. via MYRIAD GENETICS, INC.
2021 · first_quarter · Q1
Regulation of laboratory developed tests - "Verifying Accurate, Leading-edge IVCT Development (VALID) Act" - not yet introduced
Implementation of Public Law No: 116-171 (Commander John Scott Hannon Veterans Mental Health Care Improvement Act of 2019) - access to veterans mental health care services
FY21 House and Senate MilCon/VA appropriations (no bill #s); access to depression treatments for veterans
MYRIAD GENETICS, INC. via MYRIAD GENETICS, INC.
2020 · fourth_quarter · Q4
Public Law No: 116-171, Commander John Scott Hannon Veterans Mental Health Care Improvement Act of 2019, issues related to suicide reduction
PL 113-93, Protecting Access to Medicare Act of 2014; implementation of Medicare payment changes for clinical laboratory tests
CARES Act (PL 116-136), provisions concerning COVID testing, laboratories and unemployment insurance Legislation addressing barriers to the adoption of pharmacogenomic testing; not introduced
MYRIAD GENETICS, INC. via MYRIAD GENETICS, INC.
2020 · third_quarter · Q3
Regulation of laboratory developed tests "Verifying Accurate, Leading-edge IVCT Development (VALID) Act of 2020" - HR 6102/S 3404 Provisions relating to laboratories in PL 115-271 Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act; Section 8122
Medicare coverage policies for mental health genetic tests
CARES Act (PL 116-136), provisions concerning COVID testing, laboratories and unemployment insurance "COVID 4.0," legislation address impact of pandemic; provisions relating to laboratories and mental health providers
MYRIAD GENETICS, INC. via MYRIAD GENETICS, INC.
2020 · second_quarter · Q2
CARES Act (PL 116-136), provisions concerning COVID testing, laboratories and unemployment insurance "COVID 4.0," legislation not yet introduced to address impact of pandemic; provisions relating to laboratories and mental health providers
Regulation of laboratory developed tests e.g. pharmacogenomics LDTs - discussion draft in House - "Verifying Accurate, Leading-edge IVCT Development (VALID) Act of 2020" - HR 6102/S 3404 Provisions relating to laboratories in PL 115-271 Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act; Section 8122
MYRIAD GENETICS, INC. via MYRIAD GENETICS, INC.
2020 · first_quarter · Q1
Regulation of laboratory developed tests e.g. pharmacogenomics LDTs - discussion draft in House - "Verifying Accurate, Leading-edge IVCT Development (VALID) Act of 2020" - HR 6102/S 3404 Provisions relating to laboratories in PL 115-271 Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act; Section 8122
FY20 HHS Appropriations bill regarding CMS coverage policies for mental health genetic tests
Section 216(a) of the Protecting Access to Medicare Act of 2014 (PAMA - PL 113-93); payment of laboratory tests Medicare coverage policies for mental health genetic tests
MYRIAD GENETICS, INC. via MYRIAD GENETICS, INC.
2019 · fourth_quarter · Q4
Regulation of laboratory developed tests e.g. pharmacogenomics LDTs - discussion draft in House - "Verifying Accurate, Leading-edge IVCT Development (VALID) Act"; no HR # Provisions relating to laboratories in PL 115-271 Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act; Section 8122
S. 1895, the Lower Health Care Costs Act - Title I, Ending Surprise Medical Bills
FY20 HHS Appropriations bill regarding CMS coverage policies for mental health genetic tests
MYRIAD GENETICS, INC. via MYRIAD GENETICS, INC.
2019 · third_quarter · Q3
Section 216(a) of the Protecting Access to Medicare Act of 2014 (PAMA - PL 113-93); payment of laboratory tests Medicare coverage policies for mental health genetic tests
FY20 HHS Appropriations bill regarding CMS coverage policies for mental health genetic tests
S. 1895, the Lower Health Care Costs Act - Title I, Ending Surprise Medical Bills
MYRIAD GENETICS, INC. via MYRIAD GENETICS, INC.
2019 · second_quarter · Q2
Legislation to reform Section 101 of the Patent Act concerning patent eligibility; no bill introduced yet, only draft language
FY20 HHS Appropriations bill regarding CMS coverage policies for mental health genetic tests
S. 1895, the Lower Health Care Costs Act - Title I, Ending Surprise Medical Bills
MYRIAD GENETICS, INC. via MYRIAD GENETICS, INC.
2019 · first_quarter · Q1
Regulation of laboratory developed tests - discussion draft in House - "Verifying Accurate, Leading-edge IVCT Development (VALID) Act"; no HR # Provisions relating to laboratories in PL 115-271 Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act; Section 8122
Legislation to reform Section 101 of the Patent Act concerning patent eligibility; no draft or bill introduced yet
Section 216(a) of the Protecting Access to Medicare Act of 2014 (PAMA - PL 113-93); payment of laboratory tests Medicare coverage policies for mental health genetic tests
MYRIAD GENETICS, INC. via MYRIAD GENETICS, INC.
2018 · fourth_quarter · Q4
Regulation of laboratory developed tests - discussion draft in House - The Diagnostic Accuracy and Innovation Act (DAIA) and Verifying Accurate Leading-edge IVCT Development Act of 2018 (VALID); no HR #
Section 216(a) of the Protecting Access to Medicare Act of 2014 (PAMA)(PL 113-93); payment, coding and coverage for laboratory tests Crosswalk payment for BRCA CPT codes Coverage for personalized medicine tests for the treatment of major depressive disorder
Potential legislation to amend statute governing patent eligibility; section 101
MYRIAD GENETICS, INC. via MYRIAD GENETICS, INC.
2018 · third_quarter · 3A
Regulation of laboratory developed tests - discussion draft in House - The Diagnostic Accuracy and Innovation Act (DAIA); no HR #
Section 216(a) of the Protecting Access to Medicare Act of 2014 (PAMA)(PL 113-93); payment, coding and coverage for laboratory tests HR 3635, Local Coverage Determination Clarification Act of 2017; LCD process for laboratory tests
Coverage and payment of laboratory tests by the VA
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
MYRIAD GENETICS, INC. via MYRIAD GENETICS, INC.
2018 · third_quarter · RR
Payment for laboratory testing by Medicare, Medicaid, VA, DoD, TRICARE, etc. Regulation of laboratory developed tests by FDA
Payment for laboratory testing by Medicare, Medicaid, VA, DoD, TRICARE, etc. Regulation of laboratory developed tests by FDA
Section 216(a) of PL 113-93 (Protecting Access to Medicare Act of 2014; aka PAMA) - payment of laboratory tests in Medicare
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Regulation of laboratory developed tests - "Verifying Accurate, Leading-edge IVCT Development (VALID) Act" (HR 4128 / S 2209)
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Section 216(a) of PL 113-93 (Protecting Access to Medicare Act of 2014; aka PAMA) - payment of laboratory tests in Medicare
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Regulation of laboratory developed tests "Verifying Accurate, Leading-edge IVCT Development (VALID) Act of 2020" - HR 6102/S 3404
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Medicare coverage policies for mental health genetic tests
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
S. 1895, the Lower Health Care Costs Act - Title I, Ending Surprise Medical Bills
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Section 216(a) of the Protecting Access to Medicare Act of 2014 (PAMA - PL 113-93); payment of laboratory tests Medicare coverage policies for mental health genetic tests
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Regulation of laboratory developed tests e.g. pharmacogenomics LDTs - discussion draft in House - "Verifying Accurate, Leading-edge IVCT Development (VALID) Act"; no HR # Provisions relating to laboratories in PL 115-271 Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act; Section 8122
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Section 216(a) of the Protecting Access to Medicare Act of 2014 (PAMA - PL 113-93); payment of laboratory tests Medicare coverage policies for mental health genetic tests
Regulation of laboratory developed tests - discussion draft in House - "Verifying Accurate, Leading-edge IVCT Development (VALID) Act"; no HR # Provisions relating to laboratories in PL 115-271 Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act; Section 8122
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE